David M.  Clapper net worth and biography

David Clapper Biography and Net Worth

David M. Clapper has served as our President and Chief Executive Officer since May 2011 and has served as a member of the board of directors since October 2008. Mr. Clapper started his medical device career at Johnson & Johnson. During his 16 years at Johnson & Johnson, he held positions from Sales Representative to Vice President of Product Management, Sales, and Marketing, and a member of the board of directors of Ethicon Inc., Ethicon Endo-Surgery, and Critikon, Inc. In 1993, he became the President and CEO of Focal Inc. (Nasdaq: FOCL – acquired by Genzyme/Sanofi), a biomaterials company in Boston. In 1999, Mr. Clapper began serving as President and CEO of Novacept Inc. in Palo Alto, CA until its acquisition in 2004 by Cytyc Corporation. In 2005 Mr. Clapper began serving as the President and CEO of SurgRx, Inc. until its acquisition in December 2008, by Ethicon Endo-Surgery, Inc., a Johnson & Johnson company. In the past, he also served as a member of the board of directors at SVB Financial Group and Silicon Valley Bank (Nasdaq: SIVB), Pulmonx Corporation (Nasdaq: LUNG), Conor Medsystems, Inc. (Nasdaq: CONR—acquired by Johnson and Johnson), St. Francis Medical Technologies Inc., (acquired by Kyphon/Medtronic), Baxano, Inc. (acquired by TranS1), DFINE, Inc. (acquired by Merit Medical), IoGyn, Inc. (acquired by Boston Scientific Corporation (BSC)), Neomend, Inc. (acquired by CR Bard), Carbylan Therapeutics, Inc. (Nasdaq: CBYL – acquired by KalVista), and RELIGN Corporation (acquired by Zimmer-Biomet). Mr. Clapper is currently serving on the board of directors of Corinth MedTech. Mr. Clapper holds a B.A. in Marketing from Bowling Green State University.

How do I contact David M. Clapper?

The corporate mailing address for Mr. Clapper and other Minerva Surgical executives is , , . Minerva Surgical can also be reached via phone at 855-646-7874 and via email at [email protected]. Learn More on David M. Clapper's contact information.

Has David M. Clapper been buying or selling shares of Minerva Surgical?

David M. Clapper has not been actively trading shares of Minerva Surgical in the last ninety days. Most recently, on Monday, December 13th, David M. Clapper bought 1,250 shares of Minerva Surgical stock. The stock was acquired at an average cost of $98.80 per share, with a total value of $123,500.00. Learn More on David M. Clapper's trading history.

David M. Clapper Insider Trading History at Minerva Surgical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2021Buy1,250$98.80$123,500.00View SEC Filing Icon  
See Full Table

David M. Clapper Buying and Selling Activity at Minerva Surgical

This chart shows David M Clapper's buying and selling at Minerva Surgical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Minerva Surgical Company Overview

Minerva Surgical logo
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.01
Low: $0.00
High: $0.01

2 Week Range

Now: N/A

Volume

N/A

Average Volume

193 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.73